A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants with New-Onset or Relapsing Giant Cell Arteritis

Janssen-Cilag International N.V.0 sites51 target enrollmentSeptember 24, 2020

Overview

No summary available.

Registry

who.int

Start Date

September 24, 2020

End Date

TBD

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•1\. Male or female
•2\. At least 50 years of age, inclusive
•3\. Diagnosis of GCA according to the revised American College of Rheumatology criteria
•4\. Temporal artery biopsy revealing features of GCA either at time of diagnosis or at other timepoint during disease history OR, Evidence of cranial GCA either at time of diagnosis or at other timepoint during disease history by cranial doppler\-ultrasound, cranial Magnetic Resonance Imaging or Magnetic Resonance Angiography, or other imaging modality upon agreement with the sponsor OR Evidence of GCA by angiography or cross\-sectional imaging (ultrasound, MRI, CT, PET).
•5\. Have new onset or relapsing GCA
•6\. Have active GCA within 6 weeks of first study intervention
•Inclusion criterion for LTE period
•1\. Has completed Week 52 visit of the main study, AND has no signs and symptoms of active GCA, AND completed treatment study intervention according to the protocol, AND completed 26\-week protocol defined GCtaper without the need to use rescue medication for GCA, AND has not experienced a GCA flare through Week 52\.
•2\. Has not had any study intervention\-related SAE or severe AE
•3\. Is able and willing to continue (blinded) treatment with study intervention

•1\. Has any known severe or uncontrolled GCA complications
•2\. Has any rheumatic disease other than GCA such as Takayasu's Arteritis, granulomatosis with polyangiitis (Wegener's), RA, systemic
•lupus erythematosus that could interfere with assessment of GCA
•3\. Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal,
•endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
•4\.1a. Has or has had any major ischemic event, within 12 weeks of first study intervention
•4\.1b. Has a personal history of arterial thrombosis or venous thromboembolism (including deep venous thrombosis \[DVT] and Pulmonary Embolism \[PE])
•5\. Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of indetermined significance; or
•signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly
•19\. Has had a fracture of the hip or leg, major trauma or spinal cord injury, hip or knee replacement within 8 weeks before screening; had